Literature DB >> 16539635

Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression.

R Stüdeli1, S Jung, P Mohacsi, S Perruchoud, P Castiglioni, P Wenaweser, G Heimbeck, M Feller, R Hullin.   

Abstract

Previous studies demonstrated that impaired left ventricular (LV) relaxation in cardiac allografts limits exercise tolerance post-transplant despite preserved systolic ejection fraction (EF). This study tested in human cardiac allografts whether the isovolumic relaxation time (IVRT), which provides the basis for most of diastolic LV filling, relates with gene expression of regulatory proteins of calcium homeostasis or cardiac matrix proteins. Gene expression was studied in 31 heart transplant recipients (25 male, 6 female) 13-83 months post-transplant with LVEF >50%, LV end-diastolic pressure <20 mmHg, normal LV mass index and without allograft rejection or significant cardiac pathology. IVRT related with the other diastolic parameters e-wave velocity (r = -0.46; p = 0.01), e/a-wave ratio (r = -0.5; p < 0.01) but not with heart frequency (r = -0.16; p = 0.4). No relation of IVRT was observed for immunosuppression, mean rejection grade or other medication. IVRT was not related with gene expression of desmin, collagen I, phospholamban, the Na+-Ca2+ exchanger, the ryanodine receptor or interstitial fibrosis but correlated inversely with SERCA2a (r = -0.48; p = 0.02). Prolonged IVRT is associated with decreased SERCA2a expression in cardiac allografts without significant other pathology. Similar observations in non-transplanted patients with diastolic failure suggest that decreased SERCA2a expression is an important common pathomechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539635     DOI: 10.1111/j.1600-6143.2006.01241.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  16 in total

1.  Sleeve gastrectomy in obese Wistar rats improves diastolic function and promotes cardiac recovery independent of weight loss.

Authors:  Hailey Hayes; Jacob Patz; John Corbett; Muhammad Z Afzal; Jennifer Strande; Tammy L Kindel
Journal:  Surg Obes Relat Dis       Date:  2019-03-23       Impact factor: 4.734

2.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

3.  Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation.

Authors:  L Groban; M Lin; K A Kassik; R L Ingram; W E Sonntag
Journal:  Growth Horm IGF Res       Date:  2011-03-02       Impact factor: 2.372

4.  Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats.

Authors:  Leanne Groban; Hao Wang; Frederico S M Machado; Aaron J Trask; Stephen B Kritchevsky; Carlos M Ferrario; Debra I Diz
Journal:  Cardiovasc Endocrinol       Date:  2012-09-01

5.  Advances in diastolic heart failure.

Authors:  Xing Sheng Yang; Jing Ping Sun
Journal:  World J Cardiol       Date:  2010-03-26

6.  Quantification of myocardial interstitial fibrosis and extracellular volume for the detection of cardiac allograft vasculopathy.

Authors:  Ruud B van Heeswijk; Jessica A M Bastiaansen; Juan F Iglesias; Sophie Degrauwe; Samuel Rotman; Jean-Luc Barras; Julien Regamey; Nathalie Lauriers; Piergiorgio Tozzi; Jérôme Yerly; Giulia Ginami; Matthias Stuber; Roger Hullin
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-13       Impact factor: 2.357

Review 7.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

8.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

9.  SERCA2a, phospholamban, sarcolipin, and ryanodine receptors gene expression in children with congenital heart defects.

Authors:  Simona Vittorini; Simona Storti; Maria Serena Parri; Alfredo Giuseppe Cerillo; Aldo Clerico
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

Review 10.  Darier Disease - A Multi-organ Condition?

Authors:  Etty Bachar-Wikström; Jakob D Wikström
Journal:  Acta Derm Venereol       Date:  2021-04-15       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.